Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients

被引：0
|
作者：
Balamurgan, R. [1 ]
Mohan, B. [2 ]
Kodgule, R. [3 ]
Tandon, M. [3 ]
Pendse, A. [4 ]
Khaladkar, K. [5 ]
Sharath, R. [5 ]
Katare, S. [5 ]
Suryawanshi, S. [5 ]
Barkate, H. [5 ]
机构：
[1] Kovai Diabet Specialty Ctr & Hosp, Diabetol, Coimbatore, Tamil Nadu, India
[2] Brij Med Ctr Pvt Ltd, Diabetol, Kanpur, Uttar Pradesh, India
[3] Glenmark Pharmaceut Ltd, Dept Clin Dev, Mumbai, Maharashtra, India
[4] Glenmark Pharmaceut Ltd, Dept Clin Operat, Mumbai, Maharashtra, India
[5] Glenmark Pharmaceut Ltd, Dept Global Med Affairs, Mumbai, Maharashtra, India
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2022年 / 186卷
关键词：
D O I：
10.1016/j.diabres.2022.109517
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF21-0338
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real world assessment of effectiveness and safety of FDC of remogliflozin etabonate and Vildagliptin in T2DM patients
    Bhattacharyya, S.
    Katare, S.
    Khaladkar, K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [2] Phase 3 Results of Fixed -Dose Combination of Remogliflozin Etabonate and Vildagliptin in Indian T2DM Patients
    Mohan, Brij
    Chawla, Manoj S.
    Kodgule, Rahul R.
    Tandon, Monika
    Katare, Sagar
    Suryawanshi, Sachin
    Barkate, Hanmant V.
    DIABETES, 2021, 70
  • [3] A Phase IV study to assess safety and efficacy of FDC of Remogliflozin, Metformin and Vildagliptin in management of T2DM
    Mane, A.
    Bhushan, S.
    Creado, S.
    Singh, G.
    Gadkari, R.
    Suryawanshi, S.
    Barkate, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [4] A real-world clinical experience on effectiveness of remogliflozin etabonate in management of Indian patients with T2DM
    Mahapatra, H.
    Dalai, S.
    Sahoo, A.
    Khuntia, M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [5] Combination Therapy of Canagliflozin and Teneligliptin in Japanese Patients with T2DM: Results from Phase 3 Studies
    Kaku, Kohei
    Kadowaki, Takashi
    Inagaki, Nobuya
    Kondo, Kazuoki
    Nishimura, Kenichi
    Kaneko, Genki
    Maruyama, Nobuko
    Nakanishi, Nobuhiro
    Iijima, Hiroaki
    Watanabe, Yumi
    Goda, Maki
    DIABETES, 2017, 66 : A319 - A319
  • [6] T2DM treatment trial results
    Claire Greenhill
    Nature Reviews Endocrinology, 2019, 15 : 499 - 499
  • [7] Remogliflozin in Indian T2DM Patients: A Real-World Study
    Bhattacharya, Supratik
    Katare, Sagar
    DIABETES, 2020, 69
  • [8] T2DM treatment trial results
    Greenhill, Claire
    NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (09) : 499 - 499
  • [9] First Human Dose Escalation Study with Remogliflozin Etabonate (RE) in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus (T2DM)
    Kapur, Anita
    O'Connor-Semmes, Robin L.
    Hussey, Elizabeth K.
    Dobbins, Robert L.
    Tao, Wenli
    Hompesch, Marcus
    Nunez, Derek J.
    DIABETES, 2009, 58 : A136 - A136
  • [10] Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate (SGLT2 Inhibitor) and Metformin When Co-Administered in Type 2 Diabetes Mellitus (T2DM) Patients
    Hussey, Elizabeth K.
    Kapur, Anita
    O'Connor-Semmes, Robin L.
    Tao, Wenli
    Poo, Jorge L.
    Dobbins, Robert L.
    DIABETES, 2009, 58 : A157 - A157
12345